Bayer wins Schering AG

Germany’s Merck KGaA has agreed to sell its 21.8% stake in Schering AG, paving the way for rival Bayer to seize control of Schering AG. Bayer is expected to pay Merck KGaA $4.6 billion for its Schering AG stake upping the total purchase price for Schering AG to nearly $22 billion. The combined companies will form a German drug-manufacturing powerhouse to be  known as Bayer Schering Pharma. Schering AG’s product line includes several oncology drugs, including contraceptives Climara, Yasmin and Yaz -- and other specialty brands sold in the US by Schering AG affiliate Berlex.
You must be a registered member of MMM to post a comment.

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.